{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:29:25Z","timestamp":1791851365222,"version":"4.3.4"},"reference-count":58,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American Society of Hypertension"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.jash.2014.01.007","type":"journal-article","created":{"date-parts":[[2014,1,26]],"date-time":"2014-01-26T04:46:07Z","timestamp":1390711567000},"page":"262-275.e9","source":"Crossref","is-referenced-by-count":378,"title":["Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2172-0931","authenticated-orcid":false,"given":"William L.","family":"Baker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay R.","family":"Smyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4779-0850","authenticated-orcid":false,"given":"Daniel M.","family":"Riche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily M.","family":"Bourret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin W.","family":"Chamberlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William B.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jash.2014.01.007_bib1","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1177\/1060028013503626","article-title":"Canagliflozin, a novel SGLT2 inhibitor for treatment of type 2 diabetes","volume":"47","author":"Nigro","year":"2013","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jash.2014.01.007_bib2","series-title":"Invokana (canagliflozin) [Package insert]","year":"2013"},{"key":"10.1016\/j.jash.2014.01.007_bib3","unstructured":"US Food and Drug Administration. FDA approves Invokana to treat type 2 diabetes. March 29, 2013. Available at: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm345848.htm. Accessed October 3,\u00a02013."},{"key":"10.1016\/j.jash.2014.01.007_bib4","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00424-003-1202-0","article-title":"The sodium\/glucose cotransport family SLC5","volume":"447","author":"Wright","year":"2004","journal-title":"Eur J Physiol"},{"key":"10.1016\/j.jash.2014.01.007_bib5","doi-asserted-by":"crossref","first-page":"F10","DOI":"10.1152\/ajprenal.2001.280.1.F10","article-title":"Renal N+-glucose transporters","volume":"280","author":"Wright","year":"2001","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.jash.2014.01.007_bib6","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nrd3180","article-title":"SGLT2 inhibition\u2014a novel strategy for diabetes treatment","volume":"9","author":"Chao","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jash.2014.01.007_bib7","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1463-1326.2012.01558.x","article-title":"Canagliflozin improves glycemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin","volume":"14","author":"Devineni","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jash.2014.01.007_bib8","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/dom.12054","article-title":"Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise","volume":"15","author":"Stenlof","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jash.2014.01.007_bib9","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.2337\/dc12-2491","article-title":"Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial","volume":"36","author":"Schernthaner","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jash.2014.01.007_bib10","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","article-title":"Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52-week results from a randomized, double-blind, phase 3 non-inferiority trial","volume":"382","author":"Cefalu","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jash.2014.01.007_bib11","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jash.2014.01.007_bib12","unstructured":"Higgins JPT, Green S (editors): Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available at: www.cochrane-handbook.org. Accessed February 23, 2014."},{"key":"10.1016\/j.jash.2014.01.007_bib13","series-title":"Methods Guide for Effectiveness and Comparative Effectiveness Reviews","year":"2011"},{"key":"10.1016\/j.jash.2014.01.007_bib14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.jash.2014.01.007_bib15","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0895-4356(92)90054-Q","article-title":"Variance imputation for overviews of clinical trials with continuous response","volume":"45","author":"Follmann","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jash.2014.01.007_bib16","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.jash.2014.01.007_bib17","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.jash.2014.01.007_bib18","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"key":"10.1016\/j.jash.2014.01.007_bib19","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1742-1241.2009.02168.x","article-title":"Understanding heterogeneity in meta-analysis: the role of meta-regression","volume":"63","author":"Baker","year":"2009","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jash.2014.01.007_bib20","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.2337\/dc11-1926","article-title":"Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes","volume":"35","author":"Rosenstock","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jash.2014.01.007_bib21","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3810\/hp.2013.04.1020","article-title":"Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial","volume":"41","author":"Bode","year":"2013","journal-title":"Hosp Pract"},{"key":"10.1016\/j.jash.2014.01.007_bib22","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/dom.12149","article-title":"Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study","volume":"15","author":"Inagaki","year":"2013","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.jash.2014.01.007_bib23","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1007\/s00125-013-3039-1","article-title":"Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomized trial","volume":"56","author":"Lavalle-Gonzalez","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.jash.2014.01.007_bib24","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/dom.12090","article-title":"Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease","volume":"15","author":"Yale","year":"2013","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.jash.2014.01.007_bib25","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2337\/dc08-1863","article-title":"Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes","volume":"32","author":"List","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jash.2014.01.007_bib26","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.2337\/dc09-0517","article-title":"A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment","volume":"32","author":"Wilding","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jash.2014.01.007_bib27","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomized, double-blind, placebo-controlled trial","volume":"375","author":"Bailey","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jash.2014.01.007_bib28","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2337\/dc10-0612","article-title":"Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise","volume":"33","author":"Ferrannini","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jash.2014.01.007_bib29","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.2337\/dc11-0606","article-title":"Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin","volume":"34","author":"Nauck","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jash.2014.01.007_bib30","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/j.1463-1326.2011.01434.x","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial","volume":"13","author":"Strojek","year":"2011","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.jash.2014.01.007_bib31","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/j.1463-1326.2012.01659.x","article-title":"Dapagliflozin monotherapy in drug-na\u00efve patients with diabetes: a randomized-controlled trial of low-dose range","volume":"14","author":"Bailey","year":"2012","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.jash.2014.01.007_bib32","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jash.2014.01.007_bib33","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1742-1241.2012.02911.x","article-title":"Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomized controlled trial","volume":"66","author":"Henry","year":"2012","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jash.2014.01.007_bib34","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2337\/dc11-1693","article-title":"Effect of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy","volume":"35","author":"Rosenstock","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jash.2014.01.007_bib35","doi-asserted-by":"crossref","first-page":"405","DOI":"10.7326\/0003-4819-156-6-201203200-00003","article-title":"Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial","volume":"156","author":"Wilding","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jash.2014.01.007_bib36","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/dom.12047","article-title":"Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glaecemic control: a phase II multicenter, randomized, double-blind, placebo-controlled trial","volume":"15","author":"Kaku","year":"2013","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.jash.2014.01.007_bib37","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.2337\/dc12-2673","article-title":"Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes. A 24-week, randomized, double-blind, placebo-controlled trial","volume":"36","author":"Haring","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jash.2014.01.007_bib38","article-title":"Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial","author":"Kovacs","year":"2013","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.jash.2014.01.007_bib39","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/dom.12185","article-title":"Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia","volume":"15","author":"Rosenstock","year":"2013","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.jash.2014.01.007_bib40","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jdiacomp.2012.11.005","article-title":"Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus","volume":"27","author":"Fonseca","year":"2013","journal-title":"J Diab Compl"},{"key":"10.1016\/j.jash.2014.01.007_bib41","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/dom.12038","article-title":"Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study","volume":"15","author":"Wilding","year":"2013","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.jash.2014.01.007_bib42","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1463-1326.2011.01462.x","article-title":"Remogliflzin etabonate, a selective inhibitor of sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients","volume":"14","author":"Dobbins","year":"2012","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.jash.2014.01.007_bib43","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes. A systematic review and meta-analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann Intern Med"},{"issue":"Suppl 120","key":"10.1016\/j.jash.2014.01.007_bib44","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1038\/ki.2010.512","article-title":"Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans","volume":"79","author":"List","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.jash.2014.01.007_bib45","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1161\/01.HYP.19.1_Suppl.I2","article-title":"Kidneys and fluid in pressure regulation. Small volume but large pressure changes","volume":"19","author":"Guyton","year":"1992","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2014.01.007_bib46","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1097\/HJH.0b013e3283077f03","article-title":"Independent impact of obesity and fat distribution in hypertension prevalence and control in the elderly","volume":"26","author":"Redon","year":"2008","journal-title":"J Hypertens"},{"key":"10.1016\/j.jash.2014.01.007_bib47","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1136\/bmj.312.7041.1249","article-title":"INTERSALT revisited: Further analyses of 24 hour sodium excretion and blood pressure within and across populations. INTERSALT Cooperative Research Group","volume":"312","author":"Elliott","year":"1996","journal-title":"BMJ"},{"key":"10.1016\/j.jash.2014.01.007_bib48","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1161\/HYPERTENSIONAHA.108.112946","article-title":"Large artery stiffening with weight gain in humans: role of visceral fat accumulation","volume":"51","author":"Orr","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2014.01.007_bib49","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1161\/HYPERTENSIONAHA.108.111427","article-title":"Weight loss alone improves conduit and resistance artery endothelial function in young and older overweight\/obese adults","volume":"52","author":"Pierce","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2014.01.007_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-134-1-200101020-00007","article-title":"Long-term weight loss and changes in blood pressure: results of the trials of hypertension prevention, phase II","volume":"134","author":"Stevens","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jash.2014.01.007_bib51","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/174182679400100307","article-title":"The association between heart rate and blood pressure, blood lipids, and other cardiovascular risk factors","volume":"1","author":"Wannamethee","year":"1994","journal-title":"J Cardiovasc Risk"},{"key":"10.1016\/j.jash.2014.01.007_bib52","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/080370598437321","article-title":"Importance of the blood pressure-heart rate relationship","volume":"7","author":"Folkow","year":"1998","journal-title":"Blood Press"},{"key":"10.1016\/j.jash.2014.01.007_bib53","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/dom.12085","article-title":"Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials","volume":"15","author":"Wang","year":"2013","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.jash.2014.01.007_bib54","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1524-6175.2005.04784.x","article-title":"A meta-analysis of the effect of thiazolidinediones on blood pressure","volume":"8","author":"Qayyum","year":"2006","journal-title":"J Clin Hypertens"},{"key":"10.1016\/j.jash.2014.01.007_bib55","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jash.2012.02.003","article-title":"Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies","volume":"6","author":"Brown","year":"2012","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.jash.2014.01.007_bib56","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1177\/0091270008316885","article-title":"Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension","volume":"48","author":"Mistry","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jash.2014.01.007_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2796.2004.01328.x","article-title":"The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review","volume":"256","author":"Wulffele","year":"2004","journal-title":"J Int Med"},{"key":"10.1016\/j.jash.2014.01.007_bib58","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ahj.2013.05.007","article-title":"Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS) \u2013 a randomized placebo-controlled trial","volume":"166","author":"Neal","year":"2013","journal-title":"Am Heart J"}],"container-title":["Journal of the American Society of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933171114000539?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933171114000539?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T21:52:32Z","timestamp":1565128352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933171114000539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S1933171114000539"],"URL":"https:\/\/doi.org\/10.1016\/j.jash.2014.01.007","relation":{},"ISSN":["1933-1711"],"issn-type":[{"value":"1933-1711","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]}}}